proenzyme therapy

Business news, market intelligence, and global industry analysis.

The Latest

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Could Turtle Pond discoveries extend the geological story behind Kenbridge nickel? (CSE: TN)

Vision Marine Technologies expands electric boating strategy through pontoon segment leadership and SPECTR 26 launch

Vision Marine (NASDAQ: VMAR) targets pontoon dominance with SPECTR 26 electric platform strategy

Why Canuc Resources Corporation is quietly expanding its Sudbury exploration corridor (TSXV: CDA)

Could a proenzyme therapy disrupt chemotherapy’s dominance in pancreatic cancer treatment?

Can Propanc Biopharma’s PRP therapy reshape pancreatic cancer treatment? Discover what the biotech’s metastasis-focused strategy could mean for oncology.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 6, 2026